[Ravulizumab (generalized myasthenia gravis) - Benefit assessment according to § 35a SGB V]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004338
German
Original Title:
Ravulizumab (generalisierte Myasthenia gravis)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a22-115.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/a22-115_ravulizumab_nutzenbewertung-35a-sgb-v_v1-1.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Myasthenia Gravis
- Antibodies, Monoclonal, Humanized
- Complement Inactivating Agents
Keywords
- Ravulizumab
- Myasthenia Gravis
- Benefit Assessment
- NCT01997229
- NCT03920293
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.